Alopecia

David Cotter, MD, PhD, discusses diagnosing alopecia areata and selecting systemic treatments, including JAK inhibitors, from his SDPA 2025 presentation.

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.

Subgroups more likely to respond included women and those with shorter-duration, less-extensive hair loss.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

A 10-year study reveals azathioprine's impressive 93% hair regrowth rate in patients with moderate to severe alopecia, highlighting its long-term efficacy and safety.

In a new study, AI-driven personalized treatments significantly enhanced hair growth and scalp health, offering innovative solutions for hair loss management.

Significant unmet needs were found among high-quality validation studies on the internal structure of PROMs specific to alopecia areata.

A novel electrotrichogenic device shows promising results in promoting dense, thickened hair growth for male androgenetic alopecia patients.

The developement of bempikibart offers hope for effective treatment of severe alopecia areata amid unmet medical needs.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.

JAK inhibitors show promise in treating alopecia areata among Black patients, highlighting the need for inclusive clinical research and equitable access to therapies.

A recent meta-analysis evaluates the efficacy and safety of various JAK inhibitors for alopecia areata, highlighting 12 mg twice daily deuruxolitinib as the most effective treatment.

At week 24, the proportion of Asian patients achieving significant hair regrowth (SALT ≤20) was substantially higher in ritlecitinib treatment groups than in placebo groups.

According to a clinical trial and in vitro study, TTFE can promote scalp health and hair growth by 96.88% while reducing inflammation.

A two-set Mendelian randomization analysis revealed a genetic correlation between depression and androgenetic alopecia.

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

Clinicians observed a positive relationship between scalp hair regrowth and downstream treatment benefits for patients with alopecia areata.

A patient-centered approach ensures that hair loss treatments align with individual goals and medical history.

Compared to minoxidil alone, the combination therapy saw no significant differences in hair count and diameter.

When compared to the placebo, hair growth and quality significantly improved by day 180.

Researchers found patients with conditions like asthma or dermatitis are more likely to develop early, severe, and prolonged forms of alopecia areata.

“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.

The analysis findings support the potential use of zinc and vitamin D supplementation in managing alopecia areata.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

The 5% dosage showed a 6-fold increase in non-vellus hair count after just 5 weeks.

Itisha S. Jefferson, a patient advocate and medical student, discusses the significance of new ICD-10 codes for CCCA and FFA, improving diagnosis and care.

The JAK inhibitor was significantly superior in all safety and efficacy endpoints, when compared to other AA treatment options.

Patients achieved excellent new hair growth and strength when combining PRP with drug therapy after hair transplantation surgery.

The novel systemic review compared results and adverse events associated with various treatment methods.